PATENT CLAIM ANALYSIS

Application Number: 16416731
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["514", "278000"]

Abstract:
Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

Claim (Index 36):
The method of  claim 30 , wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is administered orally to the male human.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 100.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15851444', '14151106', '16384002', '15975449', '14406520']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8030700580106352
- 35 USC 102 Novelty (BERT): 0.669111918556136
- Combined Prediction Score: 0.7896742440651853
- Mean Citation Score: 538.8045
- Max Citation Score: 736.50757
- Similarity Product: 609.9616845205534

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test